Autism - Pipeline Review, H2 2011
Global Markets Direct’s, 'Autism - Pipeline Review, H2 2011', provides an overview of the Autism therapeutic pipeline. This report provides information on the therapeutic development for Autism, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Autism. 'Autism - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Autism.
- A review of the Autism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Autism pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Autism.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifyi
Autism – Pipeline Review, H2 2011 Autism - Pipeline Review, H2 2011 Reference Code: GMDHC1345IDB Publication Date: September 2011 Autism – Pipeline Review, H2 2011 GMDHC1345IDB / Pub September 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1) Autism – Pipeline Review, H2 2011 Ta b le o f Co n te n ts Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Autism Overview 9 Therapeutics Development 10 An Overview of Pipeline Products for Autism 10 Autism Therapeutics under Development by Companies 12 Autism Therapeutics under Investigation by Universities/Institutes 13 Late Stage Products 16 Comparative Analysis 16 Mid Clinical Stage Products 17 Comparative Analysis 17 Early Clinical Stage Products 18 Comparative Analysis 18 Discovery and Pre-Clinical Stage Products 19 Comparative Analysis 19 Autism Therapeutics - Products under Development by Companies 20 Autism Therapeutics - Products under Investigation by Universities/Institutes 21 Companies Involved in Autism Therapeutics Development 23 Neuropharm Group Plc 23 Shenzhen Beike Biotechnology Co., Ltd. 23 Seaside Therapeutics 24 Snowdon Inc. 24 Curemark, LLC 25 Cellceutix Pharmaceuticals, Inc. 25 Autism - Therapeutics Assessment 26 Assessment by Monotherapy Products 26 Assessment by Combination Products 27 Assessment by Route of Administration 28 Assessment by Molecule Type 30 Drug Profiles 32 CM-AT - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 STX209 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Celexa - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Mecamylamine - Drug Profile 35 Product Description 35 Autism – Pipeline Review, H2 2011 GMDHC1345IDB / Pub September 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(2) Autism – Pipeline Review, H2 2011 Mechanism of Action 35 R&D Progress 35 N-Acetylcysteine - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Trichuris Suis Ova - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 KM-391 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 N-Acetylcysteine - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Zyprexa - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Fluoxetine - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Olanzapine - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Oxytocin - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Ziprasidone - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Aripiprazole - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Succimer - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Memantine + Risperidone - Drug Profile 49 Product Description 49 Autism – Pipeline Review, H2 2011 GMDHC1345IDB / Pub September 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(3) Autism – Pipeline Review, H2 2011 Mechanism of Action 49 R&D Progress 49 Bumetanide - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Tpoiramate + Risperidone - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Oxytocin - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Pentoxifylline + Risperidone - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Risperidone + Celecoxib - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 56 Buspirone - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Sertraline - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Aripiprazole - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Aripiprazole + D-cycloserine - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Donepezil HCl - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 D-Cycloserine - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Abilify - Drug Profile 63 Product Description 63 Autism – Pipeline Review, H2 2011 GMDHC1345IDB / Pub September 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(4) Autism – Pipeline Review, H2 2011 Mechanism of Action 63 R&D Progress 63 Oxytocin - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 Risperidone - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 Program For Neurological Disorders - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 Human Cord Blood Mononuclear Cells + Human Umbilical Cord Mesenchymal Stem Cells - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Memantine - Drug Profile 68 Product Description
Pages to are hidden for
"Autism - Pipeline Review, H2 2011"Please download to view full document